Viewing Study NCT03441360

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:02 AM
Ignite Modification Date: 2026-01-08 @ 11:19 AM
Study NCT ID: NCT03441360
Status: COMPLETED
Last Update Posted: 2022-10-05
First Post: 2018-02-15
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Sponsor: Eisai Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Relapsed/Refractory Rhabdomyosarcoma View
None Non-rhabdomyosarcoma Soft Tissue Sarcoma View
None Ewing Sarcoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None eribulin mesylate View
None pediatric View